Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

Equities researchers at StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a report released on Saturday. The brokerage set a “sell” rating on the ...

Scale Biosciences (Scale Biotm), a leader in innovative and scalable single cell analysis solutions, today announced the availability of its QuantumScale Single Cell RNA kits, a set of next-generation ...

Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTACtm (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced ...

The rising global cancer incidence is a key factor driving the CD47 inhibitors market, as the demand for novel therapies grows. Recent clinical trial ...

The U.S. stock market took a hit on Friday as a wave of troubling economic news sent all major indexes tumbling. The S&P 500 suffered its worst drop in two months, sinking 1.7%, while the Dow and ...

Tinubu, APC leaders have settled on the removal of both Obasa and Meranda as House Speakers to solve the Lagos Assembly ...

Dubai, UAE: Emirates Islamic, one of the leading Islamic financial institutions in the UAE, held its forty-ninth General ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.